Científicos construyen 'aldeas celulares' para mapear la genética de la aptitud de las células cerebrales

Scientists have developed a groundbreaking method called "cell villages" to better understand the genetic factors influencing brain cell fitness, according to a recent study published in the American Journal of Human Genetics. The technique involves combining neural progenitor cells, early-stage brain cells derived from human stem cells, from multiple genetically diverse donors into a single shared culture. This allows researchers to observe how these cells behave collectively under uniform conditions, offering insights into individual genetic differences that might influence susceptibility to diseases such as autism, cancer, and neurodegenerative disorders. The research, led by Dr. Michael F. Wells, assistant professor of human genetics at the David Geffen School of Medicine at UCLA, addresses a longstanding challenge in cellular research: the difficulty of studying cell behavior across a wide range of genetic backgrounds. Traditional methods involve culturing cells individually, which is both time-consuming and prone to variability due to environmental fluctuations. By contrast, the cell village approach enables scientists to pool cells from numerous donors into a single experimental setting, reducing technical noise and increasing genetic diversity in a single experiment. Dr. Wells explained that the cell village method eliminates inconsistencies caused by minor differences in laboratory conditions, such as temperature or oxygen levels, which can obscure true biological signals. In this system, all cells are exposed to the same environment, making it easier to identify genetic influences on cell behavior. To track how each donor’s cells perform within the shared culture, the team developed a statistical tool named Townlet, designed specifically to analyze proportional data generated by the cell village experiments. The need for such a tool arises from the nature of the data collected. When cells from different donors are combined, their relative proportions change over time, creating a dynamic dataset akin to a shifting pie chart. Standard statistical methods often misinterpret these changes as biological responses rather than mathematical artifacts. Townlet was created to distinguish between these two types of variation, ensuring that observed differences reflect actual genetic or biological factors rather than artificial constraints imposed by the experimental setup. The team tested the effectiveness of their method by applying it to a question related to autism spectrum disorder. They focused on a condition associated with excessive head growth during early development, which is linked to mutations in certain genes. Using the cell village model, they were able to observe how different genetic backgrounds influenced the growth rates of neural progenitor cells. Their findings suggested that specific genetic variants correlated with altered cell proliferation patterns, providing potential clues about the underlying mechanisms contributing to this aspect of autism. Co-first author Tim Derebenskiy, a graduate student in the Wells lab, emphasized the reliability and precision of the cell village method compared to conventional approaches. He noted that the results obtained from pooled cultures consistently matched those from individual cell cultures, demonstrating the robustness of the technique. This consistency is crucial for advancing research into the genetic basis of complex diseases, where small differences in cell behavior can have significant implications for health outcomes. The development of cell villages represents a major step forward in understanding how genetic diversity affects cellular function. As the technology matures, it could facilitate large-scale studies involving thousands of genetic samples, enabling researchers to uncover previously hidden connections between specific genes and disease susceptibility. The method also opens the door for more personalized medical treatments based on an individual’s unique genetic profile, potentially leading to tailored therapies for conditions ranging from neurological disorders to cancer.